Skip to main content
SpringerLink
Log in

In search of preclinical robustness

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

Systematic engagement of statisticians in preclinical research could help address the weaknesses that are undermining the likelihood of subsequent success in drug discovery and development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Begley, G. C. & Ellis, L. M. Raise standards for preclinical cancer research. Nature 483, 531–533 (2012).

    Article  CAS  Google Scholar 

  2. Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nature Rev. Drug Discov. 10, 712 (2011).

    Article  CAS  Google Scholar 

  3. Ioannidis, J. P. Why most published research findings are false. PLoS Med. 2, e124 (2005).

    Article  Google Scholar 

  4. Lendrem, D. Statistical support to non-clinical. Pharm. Stat. 1, 71–73 (2002).

    Article  Google Scholar 

  5. Marquardt, D. W. The importance of statisticians. J. Am. Stat. Assoc. 82, 1–7 (1987).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ian S. Peers, Peter R. Ceuppens and Chris Harbron are at AstraZeneca 13F41 Mereside, Alderley Park, Macclesfield SK10 4TG, UK.,

    Ian S. Peers, Peter R. Ceuppens & Chris Harbron

Authors
  1. Ian S. Peers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter R. Ceuppens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chris Harbron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ian S. Peers.

Ethics declarations

Competing interests

Ian S. Peers, Peter R. Ceuppens and Chris Harbron all hold shares in AstraZeneca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peers, I., Ceuppens, P. & Harbron, C. In search of preclinical robustness. Nat Rev Drug Discov 11, 733–734 (2012). https://doi.org/10.1038/nrd3849

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3849

  • Springer Nature Limited

This article is cited by

Search

Navigation